Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
71.00    -1.00 (-1.39%)
Bid:
70.00
Ask:
72.00
Spread: 2.00 (2.857%)
Market Cap: £332.67m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Directorate Change

7 Jul 2006 16:07

Readybuy PLC07 July 2006 Readybuy plc Board appointments Readybuy plc (the "Company") announces the appointment of Daron Lee asnon-executive chairman and Professor Alastair Smith as a non-executive directorof the Company. The Company also announces the resignations of Colin Davies andKeith Salisbury with immediate effect. Daron Ross Lee (aged 39), commenced his career with stockbrokers Ashworth Sons &Barratt in 1987 before pursuing other opportunities within the family business.He then returned to stockbroking with WH Ireland Limited before establishingProquote Limited ("Proquote"), a business engaged in the provision of on-linestockmarket data and company information. Proquote was sold in February 2003 tothe London Stock Exchange plc and Daron remained with Proquote as its managingdirector until the end of 2004. Since then Daron has pursued a number ofpersonal business interests. Daron Lee is interested in 15,000,000 ordinary shares of 0.1p each in thecapital of the Company ("Ordinary Shares"), representing 12.06 per cent. of theissued ordinary share capital of the Company, and warrants to subscribe for7,500,000 Ordinary Shares. Professor David Alastair Maclaughlin Smith (aged 39), is a director of AvactaLimited, Avacta Analytical Limited and TT123 Limited. During the past fiveyears he has also been a director of Hebden Lodge Hotel Company Limited. He hasa degree and PhD in Physics from Manchester University and, after working in theUS for a period, took up a position at Leeds University in 1995. Alastair hasspent the last 10 years developing new biophysical technologies and applyingthem to problems in structural molecular biology. At the age of 38 he wasawarded a Chair of Molecular Biophysics for this work and he also holds theDirectorship of the Institute of Molecular Biophysics at Leeds University. There are no other disclosures required under Schedule Two (g) of the AIM rules. For further information please contact: Daron Lee, Readybuy plc Tel: 07802 88 89 11David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
21st Sep 20187:00 amRNSInvestor Meeting and Presentation
5th Sep 20187:15 amEQSHardman & Co Research: Avacta (AVCT): Capital increase for further development
5th Sep 20187:00 amRNSNotice of Results
31st Aug 20189:55 amRNSHolding(s) in Company
23rd Aug 20185:07 pmRNSHolding(s) in Company
23rd Aug 20185:06 pmRNSHolding(s) in Company
23rd Aug 201811:21 amRNSHolding(s) in Company
22nd Aug 20182:23 pmRNSHolding(s) in Company
22nd Aug 20189:20 amRNSHolding(s) in Company
17th Aug 201811:30 amRNSResult of General Meeting
6th Aug 20184:24 pmRNSHolding(s) in Company
30th Jul 20186:06 pmRNSResults of Placing and Subscription
30th Jul 201811:41 amRNSProposed Placing and Subscription to raise £11.4m
30th Jul 201810:35 amEQSHardman & Co Research: Avacta (AVCT): Ground-breaking new drug conjugate platform
24th Jul 20187:00 amRNSMajor Therapeutics Co-development Partnership
26th Jun 20181:30 pmEQSHardman & Co Research: Avacta (AVCT): Gearing up the management team
11th Jun 20187:00 amRNSAppointment of Non-Executive Chairman
31st May 201812:15 pmEQSHardman & Co Research: Avacta (AVCT): In vivo expression of Affimers
22nd May 20187:00 amRNSSuccessful Outcome of Study with FIT Biotech
30th Apr 20184:45 pmRNSHolding(s) in Company
17th Apr 20187:17 amEQSHardman & Co Research: Avacta (AVCT): Commendable rate of progress
16th Apr 20187:25 amRNSInterim Results
9th Apr 20182:58 pmRNSIssue of Equity
29th Mar 20187:00 amRNSAvacta to Present at Investor Forum
29th Mar 20187:00 amRNSDirectorate Change
13th Mar 201812:02 pmRNSDirector/PDMR Shareholding
7th Mar 20184:35 pmRNSPrice Monitoring Extension
8th Feb 20187:00 amRNSSummary of Capital Markets Day
22nd Jan 20187:00 amRNSAvacta and OncoSec to Collaborate
18th Jan 201811:26 amRNSResult of Annual General Meeting
18th Jan 20187:00 amRNSAGM Business Update and Notice of Results
15th Jan 201810:58 amRNSHardmanResearch: Affimer Drug Conjugates a reality
15th Jan 20187:00 amRNSDrug Development Partnership with Glythera
8th Jan 20187:00 amRNSCapital Markets Day Notification
4th Jan 201811:04 amRNSPDMR Dealing and Issue of Equity
3rd Jan 20187:00 amRNSPresenting at the Biotech Showcase, San Francisco
18th Dec 20174:28 pmRNSIssue of Equity
4th Dec 201711:03 amRNSPosting of Annual Report and Notice of AGM
30th Nov 201710:57 amRNSIssue of Equity
15th Nov 20177:00 amRNSCovance to Present Affimer Data at Conference
14th Nov 20173:27 pmRNSHolding(s) in Company
13th Nov 20177:00 amRNSAvacta to present at PEGS Europe
13th Nov 20177:00 amRNSAvacta to Present at Investor Evening
24th Oct 20177:00 amRNSAffimers in Scientific Publications
19th Oct 20177:00 amRNSPrivate Shareholder Update Event
16th Oct 201710:42 amRNSHardman Res.: R&D accelerated to advance assets
12th Oct 20177:00 amRNSAvacta to Present at Shares Spotlight Evening
10th Oct 20177:00 amRNSAvacta to Present at Major US Conference
9th Oct 20174:02 pmRNSDirector Dealing and Issue of Equity
5th Oct 20177:00 amRNSResearch collaboration with FIT Biotech Oy

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.